The combination of FLCWK with 5‐ FU inhibits colon cancer and multidrug resistance by activating PXR to suppress the IL ‐6/ STAT3 pathway
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Lifan Zhong und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Hainan Provincial Drug Safety Evaluation Research Center, Hainan Medical University, Haikou, China. Hauptthemen laut MEDLINE: Fluorouracil, STAT3 Transcription Factor, Colonic Neoplasms, Interleukin-6. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Natural Science Foundation of China, National Natural Science Foundation of China, Hainan Medical University Cultivation Foundation of China.
Abstract (Originalsprache)
5‐fluorouracil (5‐FU) is a preferred chemotherapeutic agent for the treatment of colon cancer. Nonetheless, its clinical effectiveness is frequently hampered by suboptimal therapeutic outcomes and the emergence of drug resistance. Therefore, there exists a pressing demand for novel therapeutic agents to circumvent chemoresistance. The pregnane X receptor (PXR) exerts a pivotal regulatory influence on the proliferation, invasion, and chemoresistance mechanisms in colon cancer. Activation of PXR drives up the transcription of the multidrug resistance gene (MDR1), thus prompting the expression of P‐glycoprotein (P‐gp) responsible for conferring tumour resistance. This study scrutinized the potential of Fengliao Changweikang (FLCWK) in augmenting the efficacy of 5‐FU in the management of colon cancer. To this end, we engineered colon cancer cells with varied levels of PXR expression via lentiviral transfection, subsequently validating the findings in nude mice. By means of MTT assays, flow cytometry apoptosis analysis, Western blotting and immunofluorescence, we probed into the prospective impacts of FLCWK and 5‐FU on cellular viability and resistance. Our results revealed that while upregulation of PXR amplified the therapeutic benefits in colon cancer treatment, it concurrently heightened resistance levels. FLCWK demonstrated a capacity to reduce P‐gp expression, with the combined administration of FLCWK and 5‐FU effectively reversing resistance mechanisms. Furthermore, activation of PXR was found to impede the IL‐6/STAT3 signalling pathway. In an effort to mimic the development of colon cancer, we established an azomethane oxide (AOM)/ dextran sodium sulfate (DSS) mouse model, showing that FLCWK bolstered the inhibitory effects of 5‐FU, impeding the progression of colon cancer. In summation, our findings point towards the potential of FLCWK in the treatment of colon cancer, particularly in strengthening the therapeutic efficacy of 5‐FU in the prevention and control of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Hainan Provincial Drug Safety Evaluation Research Center, Hainan Medical University, Haikou, China.
- Department of Key Specialist Office, Sanya Hospital of Traditional Chinese Medicine, Sanya, China.
- Center for Pharmacovigilance of Hainan Province, Hainan Medical Products Administration, Haikou, China.
- Department of Rehabilitation therapeutics, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
ORCID-Profile: Lifan Zhong, Yunqiang Chen
Förderung
- Hainan Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- Hainan Medical University Cultivation Foundation of China
- Hainan Province Clinical Medical Center (Department of TCM Rehabilitation of Sanya TCM Hospital)
Zitieren
APA
Zhong, L., Wang, Q., Kou, Z., Gan, L., Yang, Z., Pan, J., Huang, L., & Chen, Y. (2024). The combination of FLCWK with 5‐ FU inhibits colon cancer and multidrug resistance by activating PXR to suppress the IL ‐6/ STAT3 pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70185
Vancouver
Zhong L, Wang Q, Kou Z, Gan L, Yang Z, Pan J, et al. The combination of FLCWK with 5‐ FU inhibits colon cancer and multidrug resistance by activating PXR to suppress the IL ‐6/ STAT3 pathway. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70185
BibTeX
@article{Zhong2024,
author = {Zhong, Lifan and Wang, Qianru and Kou, Zhixiong and Gan, Lianfang and Yang, Zhaoxin and Pan, Junhua and Huang, Ling and Chen, Yunqiang},
title = {The combination of FLCWK with 5‐ FU inhibits colon cancer and multidrug resistance by activating PXR to suppress the IL ‐6/ STAT3 pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70185}
}
EUVIMED